Human Microbiome Based Drugs and Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1063908
  • May 2021
  • Pharmaceuticals
  • 124 Pages
The Human Microbiome Based Drugs and Diagnostics Market research report comprises of an overall in depth-analysis such as market drivers, opportunities, restraints, latest developments and trends, segmentation of the market, competitive analysis, global as well as regional analysis by showcasing how each of these factors can improve the further growth of the market on an overall perspective. The report also showcases the overall market value which includes the historic data (2018-2019) and forecast data (2020-2028) generated through the revenue (USD Mn)
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered Second Genome Inc, Enterome Bioscience, Yakult, DuPont, Vedanta BioSciences, Metabiomics Corporation, ViThera Pharmaceuticals, MicroBiome Therapeutics LLC, Merck, Osel
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Coverage
With the beginning of the COVID-19 pandemic in early 2020, all major economies around the world enforced severe lockdown restrictions to curb the spread of the virus. Apart from a few sectors such as healthcare and related essential services, most of the industries suffered tremendously due to inability to function in a normal fashion. Moreover, even some of the essential sectors suffered due to delays caused by supply chain disruptions and other travel complexities. However, with massive vaccination drives in most of the developed economies, some of the economies across the world experienced economic recovery from 2021. The Human Microbiome Based Drugs and Diagnostics market is expected to gain momentum in such economies and probably recover some of the losses inflicted in the year 2020. With continued efforts towards curbing the virus in the developing economies, the Human Microbiome Based Drugs and Diagnostics market is expected to attain Pre COVID-19 levels by mid-2022.

Human Microbiome Based Drugs and Diagnostics Report’s Assessment
The research report is formulated such that it offers a deep understating on the market drivers that are assimilating the growth of the market, the market opportunities that are going to provide future growth factors for the market and the market restraints which showcase the reasons as to why the market can get hampered and dissimilated. All these factors are considered keeping in view the historic and forecast analysis which can enlighten the above mentioned factors.

Thereby at a glance a reader can understand all the factors and prospects of the Human Microbiome Based Drugs and Diagnostics market and how it can assimilate and dissimilate based on each of the factors and figures mentioned in the report

Human Microbiome Based Drugs and Diagnostics Market Competitive and Premeditated Analysis
In the Human Microbiome Based Drugs and Diagnostics report major factors such latest tactical developments, competitors, research and development, participation of each region in the market and the competition among them, the latest news regarding company acquisitions and product launch, revenue of the competitors as well as the key offerings they provide all these factors are mentioned in the report with reasons to justify and understand them in depth.

The readers and purchaser of the Human Microbiome Based Drugs and Diagnostics research report can gain a comprehensive understanding of the market competition, the revenue of each major players and their contribution towards the market, attractive proposition analysis is provided in the report which sub divides the segments with respect to the largest segment that has contributed to the market growth and the fastest growing segment based on the size of the market as well as its overall appeal.
 
Major Key Players for Global Human Microbiome Based Drugs and Diagnostics Market:
The Human Microbiome Based Drugs and Diagnostics market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Second Genome Inc, Enterome Bioscience, Yakult, DuPont, Vedanta BioSciences, Metabiomics Corporation, ViThera Pharmaceuticals, MicroBiome Therapeutics LLC, Merck, Osel

The Human Microbiome Based Drugs and Diagnostics market report showcases vast potentials of growth and assimilation which is going to provide the industry numerous opportunities to grow and generate revenue by understanding the segments and which segment is a potential part to increase the disposable income in the present and upcoming years.

Human Microbiome Based Drugs and Diagnostics Market Segmentation Analysis:
Each of the segment is explained in brief along with the revenue it generates for the market based on the historic and forecast data by highlighting the largest segment and the fastest growing segment with reasons to justify it.

The Global segmentation of the Human Microbiome Based Drugs and Diagnostics market:
By Product
Food
Probiotics
Prebiotics
Medical Food
Diagnostic Devices
Drugs
Other Probiotic Supplements
Application
Therapeutics
Diagnnostics
Disease
Acute Diarrhea
Obesity
Diabetes
Autoimmune Disorders
Cancer
Mental Disorders
Other Diseases
Research Spending
product Type
Instruments
Consumables
Research spending
Technology Type
Cell Culture Technology
High Throughput Technology
Omics Technology

Regional Analysis of the Human Microbiome Based Drugs and Diagnostics market:
The Human Microbiome Based Drugs and Diagnostics market is dived based on different regions such as North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. And the analysis of each region is provided by highlighting the largest contribution region, the fastest growing region and the factors that is keeping the market active in the other regions is also mentioned in depth. Each regional segment also comprises of the revenue each segment holds in a specific region with reasons to justify the values.

By Regions:
  • North America (U.S and Canada)
  • Europe (U.K., Germany and France)
  • Asia Pacific (China, India and Japan)
  • Latin America (Mexico and Brazil)
  • Middle East and Africa (GCC Countries and South Africa)
 


Major Factors Included and highlighted in the Human Microbiome Based Drugs and Diagnostics report are as follows:
  • The overall market value along with historic and future data analysis.
  • The Growth drivers, opportunities and restraints are mention in detail.
  • The size of the entire Human Microbiome Based Drugs and Diagnostics market on a global perspective.
  • The CAGR value of the overall market from 2020 to 2028.
  • COVID-19 impact on the Human Microbiome Based Drugs and Diagnostics market and how it is coping up with the situation.
  • Major competitors and their contribution towards the market.
  • The segmentation analysis is included which provides a clear picture of the market bifurcation.
  • Tables and graphs that can easily been understood at a glance
  • Latest trends and news related to the Human Microbiome Based Drugs and Diagnostics market is included in the report.
Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Human Microbiome Based Drugs and Diagnostics market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Human Microbiome Based Drugs and Diagnostics market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Human Microbiome Based Drugs and Diagnostics market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Human Microbiome Based Drugs and Diagnostics market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Human Microbiome Based Drugs and Diagnostics market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Second Genome Inc
  • Enterome Bioscience
  • Yakult
  • DuPont
  • Vedanta BioSciences
  • Metabiomics Corporation
  • ViThera Pharmaceuticals
  • MicroBiome Therapeutics LLC
  • Merck
  • Osel
  • Food
  • Probiotics
  • Prebiotics
  • Medical Food
  • Diagnostic Devices
  • Drugs
  • Other Probiotic Supplements
  • Technology Type
  • Cell Culture Technology
  • High Throughput Technology
  • Omics Technology

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Human Microbiome Based Drugs and Diagnostics Market Snapshot
          2.1.1. Global Human Microbiome Based Drugs and Diagnostics Market By Product,2019
               2.1.1.1.Food
               2.1.1.2.Probiotics
               2.1.1.3.Prebiotics
               2.1.1.4.Medical Food
               2.1.1.5.Diagnostic Devices
               2.1.1.6.Drugs
               2.1.1.7.Other Probiotic Supplements
          2.1.2. Global Human Microbiome Based Drugs and Diagnostics Market By Research spending,2019
               2.1.2.1.Technology Product
               2.1.2.2.Cell Culture Technology
               2.1.2.3.High Throughput Technology
               2.1.2.4.Omics Technology
          2.1.3. Global Human Microbiome Based Drugs and Diagnostics Market By End-use,2019
          2.1.4. Global Human Microbiome Based Drugs and Diagnostics Market By Geography,2019

3. Global Human Microbiome Based Drugs and Diagnostics Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Product, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Product, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Product, 2020
     4.2. Global Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Product, 2018 – 2028

5. Global Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Research spending, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Research spending, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Research spending, 2020
     5.2. Global Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Research spending, 2018 – 2028

6. Global Human Microbiome Based Drugs and Diagnostics Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Human Microbiome Based Drugs and Diagnostics Market Size (US$), By End-use, 2018 – 2028

7. Global Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Human Microbiome Based Drugs and Diagnostics Market Analysis, 2018 – 2028 
          7.2.1. North America Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Product, 2018 – 2028
          7.2.3. North America Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Research spending, 2018 – 2028
          7.2.4. North America Human Microbiome Based Drugs and Diagnostics Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Human Microbiome Based Drugs and Diagnostics Market Analysis, 2018 – 2028 
          7.3.1.  Europe Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Product, 2018 – 2028
          7.3.3. Europe Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Research spending, 2018 – 2028
          7.3.4. Europe Human Microbiome Based Drugs and Diagnostics Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Human Microbiome Based Drugs and Diagnostics Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Product, 2018 – 2028
          7.4.3. Asia Pacific Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Research spending, 2018 – 2028
          7.4.4. Asia Pacific Human Microbiome Based Drugs and Diagnostics Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Human Microbiome Based Drugs and Diagnostics Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Product, 2018 – 2028
          7.5.3. Latin America Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Research spending, 2018 – 2028
          7.5.4. Latin America Human Microbiome Based Drugs and Diagnostics Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Human Microbiome Based Drugs and Diagnostics Market Analysis, 2018 – 2028 
          7.6.1.  MEA Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Product, 2018 – 2028
          7.6.3. MEA Human Microbiome Based Drugs and Diagnostics Market Size (US$), By Research spending, 2018 – 2028
          7.6.4. MEA Human Microbiome Based Drugs and Diagnostics Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Human Microbiome Based Drugs and Diagnostics Providers
        8.4.1 Second Genome Inc
                8.4.1.1 Business Description
                8.4.1.2 Second Genome Inc Geographic Operations
                8.4.1.3 Second Genome Inc Financial Information
                8.4.1.4 Second Genome Inc Product Positions/Portfolio
                8.4.1.5 Second Genome Inc Key Developments
        8.4.2 Enterome Bioscience
                8.4.2.1 Business Description
                8.4.2.2 Enterome Bioscience Geographic Operations
                8.4.2.3 Enterome Bioscience Financial Information
                8.4.2.4 Enterome Bioscience Product Positions/Portfolio
                8.4.2.5 Enterome Bioscience Key Developments
        8.4.3 Yakult
                8.4.3.1 Business Description
                8.4.3.2 Yakult Geographic Operations
                8.4.3.3 Yakult Financial Information
                8.4.3.4 Yakult Product Positions/Portfolio
                8.4.3.5 Yakult Key Developments
        8.4.4 DuPont
                8.4.4.1 Business Description
                8.4.4.2 DuPont Geographic Operations
                8.4.4.3 DuPont Financial Information
                8.4.4.4 DuPont Product Positions/Portfolio
                8.4.4.5 DuPont Key Developments
        8.4.5 Vedanta BioSciences
                8.4.5.1 Business Description
                8.4.5.2 Vedanta BioSciences Geographic Operations
                8.4.5.3 Vedanta BioSciences Financial Information
                8.4.5.4 Vedanta BioSciences Product Positions/Portfolio
                8.4.5.5 Vedanta BioSciences Key Developments
        8.4.6 Metabiomics Corporation
                8.4.6.1 Business Description
                8.4.6.2 Metabiomics Corporation Geographic Operations
                8.4.6.3 Metabiomics Corporation Financial Information
                8.4.6.4 Metabiomics Corporation Product Positions/Portfolio
                8.4.6.5 Metabiomics Corporation Key Developments
        8.4.7 ViThera Pharmaceuticals
                8.4.7.1 Business Description
                8.4.7.2 ViThera Pharmaceuticals Geographic Operations
                8.4.7.3 ViThera Pharmaceuticals Financial Information
                8.4.7.4 ViThera Pharmaceuticals Product Positions/Portfolio
                8.4.7.5 ViThera Pharmaceuticals Key Developments
        8.4.8 MicroBiome Therapeutics LLC
                8.4.8.1 Business Description
                8.4.8.2 MicroBiome Therapeutics LLC Geographic Operations
                8.4.8.3 MicroBiome Therapeutics LLC Financial Information
                8.4.8.4 MicroBiome Therapeutics LLC Product Positions/Portfolio
                8.4.8.5 MicroBiome Therapeutics LLC Key Developments
        8.4.9 Merck
                8.4.9.1 Business Description
                8.4.9.2 Merck Geographic Operations
                8.4.9.3 Merck Financial Information
                8.4.9.4 Merck Product Positions/Portfolio
                8.4.9.5 Merck Key Developments
        8.4.10 Osel
                8.4.10.1 Business Description
                8.4.10.2 Osel Geographic Operations
                8.4.10.3 Osel Financial Information
                8.4.10.4 Osel Product Positions/Portfolio
                8.4.10.5 Osel Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Human Microbiome Based Drugs and Diagnostics Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Human Microbiome Based Drugs and Diagnostics Market Revenue, By Product, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Human Microbiome Based Drugs and Diagnostics Market Revenue, By Research spending, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Human Microbiome Based Drugs and Diagnostics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Human Microbiome Based Drugs and Diagnostics Market Revenue, By Product, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Human Microbiome Based Drugs and Diagnostics Market Revenue, By Research spending, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Human Microbiome Based Drugs and Diagnostics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Human Microbiome Based Drugs and Diagnostics Market Revenue, By Product, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Human Microbiome Based Drugs and Diagnostics Market Revenue, By Research spending, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Human Microbiome Based Drugs and Diagnostics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Human Microbiome Based Drugs and Diagnostics Market Revenue, By Product, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Human Microbiome Based Drugs and Diagnostics Market Revenue, By Research spending, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Human Microbiome Based Drugs and Diagnostics Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Human Microbiome Based Drugs and Diagnostics Market Revenue, By Product, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Human Microbiome Based Drugs and Diagnostics Market Revenue, By Research spending, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Human Microbiome Based Drugs and Diagnostics Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Human Microbiome Based Drugs and Diagnostics: Market Segmentation 
FIG. 2 Global Human Microbiome Based Drugs and Diagnostics Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Human Microbiome Based Drugs and Diagnostics Market, By Product, 2019 (US$ Mn) 
FIG. 5 Global Human Microbiome Based Drugs and Diagnostics Market, By Research spending, 2019 (US$ Mn) 
FIG. 6 Global Human Microbiome Based Drugs and Diagnostics Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Human Microbiome Based Drugs and Diagnostics Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Human Microbiome Based Drugs and Diagnostics Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Human Microbiome Based Drugs and Diagnostics Providers, 2019
FIG. 11 Global Human Microbiome Based Drugs and Diagnostics Market Revenue Contribution, By Product, 2019 & 2028 (Value %) 
FIG. 12 Global Human Microbiome Based Drugs and Diagnostics Market Revenue Contribution, By Research spending, 2019 & 2028 (Value %) 
FIG. 13 Global Human Microbiome Based Drugs and Diagnostics Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Human Microbiome Based Drugs and Diagnostics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Human Microbiome Based Drugs and Diagnostics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Human Microbiome Based Drugs and Diagnostics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Human Microbiome Based Drugs and Diagnostics Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Human Microbiome Based Drugs and Diagnostics Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Human Microbiome Based Drugs and Diagnostics market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Human Microbiome Based Drugs and Diagnostics Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Human Microbiome Based Drugs and Diagnostics Market Value, By Segment1, 2018 – 2028
TABLE  North America Human Microbiome Based Drugs and Diagnostics Market Value, By Segment2, 2018 – 2028
TABLE  North America Human Microbiome Based Drugs and Diagnostics Market Value, By Country, 2018 – 2028
TABLE  Europe Human Microbiome Based Drugs and Diagnostics Market Value, By Segment1, 2018 – 2028
TABLE  Europe Human Microbiome Based Drugs and Diagnostics Market Value, By Segment2, 2018 – 2028
TABLE  Europe Human Microbiome Based Drugs and Diagnostics Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Human Microbiome Based Drugs and Diagnostics Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Human Microbiome Based Drugs and Diagnostics Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Human Microbiome Based Drugs and Diagnostics Market Value, By Country, 2018 – 2028
TABLE  Latin America Human Microbiome Based Drugs and Diagnostics Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Human Microbiome Based Drugs and Diagnostics Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Human Microbiome Based Drugs and Diagnostics Market Value, By Country, 2018 – 2028
TABLE  MEA Human Microbiome Based Drugs and Diagnostics Market Value, By Segment1, 2018 – 2028
TABLE  MEA Human Microbiome Based Drugs and Diagnostics Market Value, By Segment2, 2018 – 2028
TABLE  MEA Human Microbiome Based Drugs and Diagnostics Market Value, By Country, 2018 – 2028
TABLE  Second Genome Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Enterome Bioscience: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Yakult: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  DuPont: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Vedanta BioSciences: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Metabiomics Corporation: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ViThera Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  MicroBiome Therapeutics LLC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Merck: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Osel: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Human Microbiome Based Drugs and Diagnostics Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Human Microbiome Based Drugs and Diagnostics Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Human Microbiome Based Drugs and Diagnostics Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Human Microbiome Based Drugs and Diagnostics Market, By Geography, 2019 (US$ Mn)
FIG.  Global Human Microbiome Based Drugs and Diagnostics Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Human Microbiome Based Drugs and Diagnostics Providers, 2016
FIG.  Global Human Microbiome Based Drugs and Diagnostics Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Probiotics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Prebiotics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Medical Food Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Diagnostic Devices Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Other Probiotic Supplements Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Human Microbiome Based Drugs and Diagnostics Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Cell Culture Technology Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global High Throughput Technology Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Omics Technology Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Human Microbiome Based Drugs and Diagnostics Market Value, 2018 – 2028, (US$ Mn)